Aziyo Biologics, Inc. (NASDAQ:AZYO) Short Interest Update

Aziyo Biologics, Inc. (NASDAQ:AZYO) was the target of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 1,800 shares, a decrease of 88.4% from the December 15th total of 15,500 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average daily volume of 16,700 shares, the short-interest ratio is currently 0.1 days.

In other news, Director Highcape Capital, L.P. acquired 412,735 shares of the business’s stock in a transaction dated Wednesday, December 8th. The shares were acquired at an average cost of $4.24 per share, with a total value of $1,749,996.40. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Thomas Englese acquired 4,580 shares of the business’s stock in a transaction dated Tuesday, December 14th. The stock was purchased at an average cost of $6.10 per share, for a total transaction of $27,938.00. The disclosure for this purchase can be found here. 45.00% of the stock is currently owned by corporate insiders.

Hedge funds have recently modified their holdings of the business. O Shaughnessy Asset Management LLC purchased a new position in Aziyo Biologics during the second quarter worth approximately $28,000. Morgan Stanley lifted its position in shares of Aziyo Biologics by 370.0% in the second quarter. Morgan Stanley now owns 3,295 shares of the company’s stock valued at $32,000 after acquiring an additional 2,594 shares in the last quarter. Ergoteles LLC purchased a new position in shares of Aziyo Biologics in the second quarter valued at approximately $96,000. Millennium Management LLC lifted its position in shares of Aziyo Biologics by 73.0% in the third quarter. Millennium Management LLC now owns 28,550 shares of the company’s stock valued at $202,000 after acquiring an additional 12,047 shares in the last quarter. Finally, Birchview Capital LP purchased a new position in shares of Aziyo Biologics in the second quarter valued at approximately $288,000. Institutional investors own 80.18% of the company’s stock.

A number of brokerages have recently commented on AZYO. Piper Sandler lowered their target price on Aziyo Biologics from $14.00 to $11.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 9th. Cantor Fitzgerald restated an “overweight” rating on shares of Aziyo Biologics in a research note on Thursday, November 11th. Finally, Zacks Investment Research upgraded Aziyo Biologics from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research note on Tuesday.

Shares of AZYO opened at $7.00 on Friday. Aziyo Biologics has a 52 week low of $4.10 and a 52 week high of $18.20. The company has a quick ratio of 1.31, a current ratio of 1.74 and a debt-to-equity ratio of 1.53. The company has a market capitalization of $71.80 million, a price-to-earnings ratio of -3.32 and a beta of 0.80. The stock’s 50-day moving average price is $5.96 and its 200-day moving average price is $7.03.

Aziyo Biologics (NASDAQ:AZYO) last issued its quarterly earnings results on Monday, November 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.19). The business had revenue of $11.49 million for the quarter, compared to analysts’ expectations of $11.54 million. Aziyo Biologics had a negative return on equity of 140.59% and a negative net margin of 43.12%. During the same quarter in the prior year, the company posted ($15.79) EPS. As a group, equities analysts anticipate that Aziyo Biologics will post -1.87 EPS for the current fiscal year.

Aziyo Biologics Company Profile

Aziyo Biologics, Inc, a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device; and cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons.

Featured Story: Diluted Earnings Per Share

Receive News & Ratings for Aziyo Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aziyo Biologics and related companies with MarketBeat.com's FREE daily email newsletter.